# CALC catalysts: CalciMedica, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/calc/catalysts

> CalciMedica, Inc. (CALC) has 2 upcoming catalysts. The next is the CalciMedica, Inc. topline data readout, December 31, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CALC?

CalciMedica, Inc. (CALC) has 2 upcoming catalysts. The next is the CalciMedica, Inc. topline data readout, December 31, 2026. SEC Form 10-Q: "Warrants were exercisable immediately upon issuance and will expire upon the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from a Phase 2 clinical trial in patients with acute kidney injury." [Calendar and source filings](https://sec-api.dev/companies/calc/catalysts)

Source: SEC Form 10-Q, accession 0001193125-26-455490, https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/calc/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CalciMedica, Inc. |
| Ticker | CALC (Nasdaq) |
| SEC CIK | 1534133 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/calc |

## Cash runway

Cash $13.8M as of 2026-09-30; quarterly burn $3.9M; about 10.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-455490).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2024 | [CM5480 trial start](https://sec-api.dev/pdufa/cm5480) | CALC |  | completed | "We also initiated a Phase 2 trial of Auxora in AKI in July 2024, which we refer to as KOURAGE." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm)) |
| November 13, 2024 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-ex99_1.htm)) |
| 2025 | [CalciMedica, Inc. topline data readout](https://sec-api.dev/companies/calc/catalysts) | CALC | severe AKI, with enrollment ongoing and topline data | scheduled | "We are committed to working closely with the FDA to design a pivotal program for Auxora in AP, and we continue to make progress in KOURAGE, our Phase 2 trial of Auxora in patients with severe AKI, with enrollment ongoing and topline data expected in 2025."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-ex99_1.htm)) |
| 2025 | [CalciMedica, Inc. topline data readout](https://sec-api.dev/companies/calc/catalysts) | CALC |  | scheduled | "Topline data are expected in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-ex99_1.htm)) |
| March 27, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/ck0001534133-ex99_1.htm)) |
| May 14, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025070910/ck0001534133-ex99_1.htm)) |
| August 12, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/ck0001534133-ex99_1.htm)) |
| November 12, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/ck0001534133-ex99_1.htm)) |
| Jan 2026 | [CM5480 trial start](https://sec-api.dev/pdufa/cm5480) | CALC | acute kidney injury | completed | "The Company initiated a Phase 2 trial (KOURAGE; NCT06374797) evaluating Auxora in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF); in January 2026, CalciMedica paused enrollment in the trial following a recommendation from the Independent Data Monitoring Committee and, as a next step, plans to discuss potential future development in AKI with the FDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-ex99_1.htm)) |
| early 2026 | [CalciMedica, Inc. topline data readout](https://sec-api.dev/companies/calc/catalysts) | CALC |  | scheduled | "We look forward to the readout of our Phase 2 KOURAGE trial expected in early 2026," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/ck0001534133-ex99_1.htm)) |
| March 2, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports 2025 Financial Results and Provides Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/ck0001534133-ex99_1.htm)) |
| April 6, 2026 | [Auxora primary completion](https://sec-api.dev/pdufa/auxora) | CALC | Acute Kidney Injury | withdrawn | "NCT06374797 (A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor CalciMedica, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06374797)) |
| May 12, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-ex99_1.htm)) |
| August 11, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/ck0001534133-ex99_1.htm)) |
| November 10, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526454430/ck0001534133-ex99_1.htm)) |
| December 31, 2026 | [CalciMedica, Inc. topline data readout](https://sec-api.dev/companies/calc/catalysts) | CALC | acute kidney injury | scheduled | "Warrants were exercisable immediately upon issuance and will expire upon the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from a Phase 2 clinical trial in patients with acute kidney injury." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm)) |
| 2H 2027 | [CM5480 topline data readout](https://sec-api.dev/pdufa/cm5480) | CALC |  | scheduled | "Specifically, we expect that our cash, cash equivalents and short-term investments will allow us to fund our current operating plan into the second half of 2027 through the anticipated data readout of our planned Phase 1b proof-of-concept study of Auxora in patients with PH and our planned submission of an IND for CM5480 in PH." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm)) |

## Drugs

- [Auxora](https://sec-api.dev/pdufa/auxora): Acute Kidney Injury
- [CM5480](https://sec-api.dev/pdufa/cm5480): acute kidney injury

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/calc/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CALC catalysts: CalciMedica, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/calc/catalysts

```bibtex
@misc{secapidev_companies_calc_catalysts_20261116,
  title        = {CALC catalysts: CalciMedica, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/calc/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_calc_catalysts_20261116","title":"CALC catalysts: CalciMedica, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/calc/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
